Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda in Stage IB Gastric Cancer
NCT01917552Phase 3Recruiting
- Sponsor
- Asan Medical Center
- Start
- Aug 2013
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in gastric cancer (GC), sponsored by Asan Medical Center. Started Aug 2013; status: recruiting.
02
Drugs
capecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01917552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01917552.